Viela Bio, the MedImmune spinout that has attracted more than $300 million in venture capital, filed for a $150 million initial public offering last week.
Tagged with: Viela BioRead More »
September 3, 2019 Comments Off on Gaithersburg-based Viela Bio files for $150M IPO
August 20, 2018 Comments Off on Viela Bio begins clinical trials months after $250M spinoff
One of Maryland’s best-funded biotech companies took a milestone first step Monday, announcing it has begun clinical trials of a medication it is developing. Gaithersburg-based Viela Bio was spun out of MedImmune, a subsidiary of AstraZeneca, last month with $250 million in ...Read More »
April 11, 2018 Comments Off on Md. continues venture capital momentum with $405 million in Q1
Maryland companies continued last year’s strong performance in receiving venture capital investments, sparked by the large Viela Bio deal, according to the quarterly MoneyTree Report from PricewaterhouseCoopers LLP and CB Insights. With more than $405 million invested last quarter, Maryland ...Read More »
February 28, 2018 Comments Off on With $250M from investors, Viela Bio out on its own
MedImmune spun out Viela Bio as an independent biotechnology company with $250 million in Series A financing and six potential medicines, the companies announced Wednesday. Viela Bio will be based in Gaithersburg and will focus on inflammation and autoimmunity biologics, ...Read More »
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.